Arctech Innovation announces it has opened its £5M Series A fund raise, supported by fundraising advisory firm Primary Access & Research. The upcoming raise will support the development and commercialisation of its data-driven, odour-based technologies which detect or protect against the world’s deadliest diseases, such as malaria and COVID-19.

A key focus will be the ongoing development and commercialisation of Arctech Innovation’s next generation of wearable, hand-held and static devices capable of analysing odour biomarker compounds that indicate the presence of infection on a person or within an enclosed space. These unique, breakthrough technologies offer a rapid and non-invasive diagnostic testing solution, using artificial intelligence software to ensure symptomatic and asymptomatic infections are identified swiftly with real-time alerts. Further, novel wearable and home-based devices which are designed to effectively attract or repel pest insects including mosquitoes and bed bugs will also be commercialised.

The funding will enable Arctech Innovation to commercialise its pipeline of disruptive products, with accompanying intellectual property (IP) via its proprietary platform, Semeion IQ™, for deployment at scale in clinical and non-clinical settings globally.

Arctech Innovation is a spin-out company from the London School of Hygiene & Tropical Medicine, launched with a mission to save lives by creating and delivering public health innovation and global social impact. The company was co-founded by its CEO, Professor James Logan, and Professor Mary Cameron, both world-leading experts in disease control.

Arctech Innovation comprises a world-class team of research scientists and product development experts with decades of experience in entomology, clinical trials, chemical ecology and microbiology, and boasts a high-calibre portfolio of commercial clients and partners, and a unique access to clinical facilities and field sites, globally.

In January 2021, Arctech Innovation launched its first commercial product, BugScents™, a novel bed bug pheromone-based lure. It is selling successfully in the European pest control market, with exciting expansion plans for the US and Asia.

“We are excited to announce the opening of Arctech Innovation’s Series A fund raise which will allow us to accelerate the development and commercialisation of several game-changing technologies for diseases including COVID-19, and to improve health and wellbeing of people around the world, which is at the forefront of our mission,” says Professor James Logan, CEO and co-founder of Arctech Innovation.

Professor Mary Cameron, co-founder of Arctech Innovation, added: “The fight against COVID-19 is far from over, and we are seeing an alarming upward trend in malaria deaths. Future pandemics will be more frequent – investment in novel tools is urgently needed for this new era of public health.”